1. Galderisi S, Merlotti E, Mucci A (2015) Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-015-0590-4
2. Garcia-Portilla MP, Garcia-Alvarez L, Saiz PA, Al-Halab S, Bobes-Bascaran MT, Bascaran MT, Muñiz J, Bobes J (2015) Psychometric evaluation of the negative syndrome of schizophrenia. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-015-0595-z
3. Möller H-J, Czobor P (2015) Pharmacological treatment of negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-015-0596-y
4. Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A (2015) Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-015-0605-1
5. Hasan A, Wolff-Menzler C, Pfeiffer S, Falkai P, Weidinger E, Jobst A, Hoell I, Malchow B, Yeganeh-Doost P, Strube W, Quast S, Müller N, Wobrock T (2015) Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-015-0618-9